# Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD

> **NCT05942963** · PHASE4 · UNKNOWN · sponsor: **Jinnah Postgraduate Medical Centre** · enrollment: 240 (estimated)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease
- Type2diabetes

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Pioglitazone 15mg
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT05942963
- **Lead sponsor:** Jinnah Postgraduate Medical Centre
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10
- **Primary completion:** 2024-04
- **Final completion:** 2024-04
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2023-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05942963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05942963, "Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05942963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*